Semaglutide Cost in 2026: Wegovy, Ozempic & Compounded

Semaglutide cost ranges from about $25 to roughly $1,400 per month in 2026 depending on which product you buy, who's dispensing it, and what your insurance does. That 56-fold spread is wide enough to change whether the drug is realistic for you, so the details matter. Several of the branches in this decision tree were redrawn after the FDA confirmed the semaglutide injection shortage was resolved in early 2025.

This guide covers US adult pricing for Wegovy, Ozempic, and Rybelsus, the cash-pay options Novo Nordisk runs through NovoCare Pharmacy, manufacturer savings cards, and the post-2025 compounded market. For clinical decisions, work with a licensed prescriber.

How much does semaglutide cost in 2026?

The chart below shows what semaglutide costs across the main 2026 paths, before getting into the details of each.

How much do Wegovy and Ozempic cost without insurance?

Semaglutide is the same active ingredient in three different Novo Nordisk products, approved for different indications:

• Wegovy, FDA approved for chronic weight management in adults and adolescents and, since 2024, for reducing the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease.
• Ozempic, FDA approved for Type 2 diabetes mellitus and for reducing major cardiovascular events in adults with Type 2 diabetes and established cardiovascular disease.
• Rybelsus, the oral tablet form of semaglutide, approved for Type 2 diabetes.

The drug molecule, manufactured by Novo Nordisk, is the same in each product. The pricing differs because the products differ in dose, formulation, and targeted indication.

Wegovy List Price

According to Novo Nordisk's NovoCare patient pricing page, the list price for Wegovy is $1,349.02 per package, and the same list price applies to all three formulations: the standard pens (0.25 mg through 2.4 mg), the Wegovy HD 7.2 mg pen, and the new Wegovy oral tablets.¹ Without insurance, retail pharmacies typically charge close to this list price plus dispensing margins.

At list price, a Wegovy patient paying out of pocket and using one package per month would spend roughly $16,200 per year, before any savings card or NovoCare direct discount.

Ozempic List Price

The list price for Ozempic is $1,027.51 per fill, the same across the 0.25 mg / 0.5 mg starter pen, the 1 mg pen, and the 2 mg maintenance pen.² A patient paying cash for Ozempic at list price would spend roughly $12,300 per year before any discounts.

How much is semaglutide through NovoCare Pharmacy direct?

In 2025, Novo Nordisk expanded NovoCare Pharmacy, a direct-to-patient cash-pay channel that ships Wegovy and Rybelsus at prices well below retail. The model resembles what Eli Lilly built with LillyDirect for Zepbound: a manufacturer-run cash-pay path that bypasses the standard pharmacy supply chain.

Wegovy NovoCare Direct Pricing (April 2026)

Source: Novo Nordisk Wegovy NovoCare Pharmacy direct pricing, retrieved April 20, 2026.¹ Requires valid US prescription. Not combinable with the Wegovy savings card.

Rybelsus NovoCare Direct Pricing

Rybelsus, the oral tablet form of semaglutide, is offered through NovoCare Pharmacy at $149 per month for the 1.5 mg and 4 mg tablets. The 4 mg intro price runs through August 31, 2026, after which the 4 mg tablet moves to $199 per month.³

For a Wegovy patient maintained at the 2.4 mg target dose who refills consistently through NovoCare, annual cost runs $4,188 per year, compared to roughly $16,200 at list price. That is a savings of about $12,000 per year for the same FDA-approved Wegovy from Novo Nordisk.

A few practical notes on NovoCare Pharmacy direct:

• This is brand-name Wegovy or Rybelsus, made and shipped by Novo Nordisk. It is not compounded, not generic, and not repackaged.
• NovoCare direct is a cash-pay program. It cannot be combined with the manufacturer savings card or with insurance billing.
• Eligibility requires a valid US prescription and a US shipping address. Patients enrolled in federal programs (Medicare, Medicaid, TRICARE, VA) can purchase through NovoCare direct, since this is a cash transaction not run through insurance.
• There is no current NovoCare direct cash-pay channel for Ozempic. Type 2 diabetes patients more frequently have insurance coverage that makes cash-pay less attractive, mirroring the same logic Eli Lilly applies to Mounjaro.

How much is semaglutide with insurance and a savings card?

Novo Nordisk runs manufacturer savings programs for Wegovy and Ozempic. The structures are similar: commercial insurance required, federal program beneficiaries excluded.

Wegovy Savings Card

Commercially insured Wegovy patients can pay as little as $25 per month with the Wegovy savings card, subject to a maximum of $100 per month in savings.¹ The card is structured as a copay buydown, so the actual out-of-pocket cost depends on what the plan would otherwise charge. For patients whose commercial plan does not cover Wegovy, a smaller flat discount may still apply, though Wegovy directs the majority of cash-pay patients to NovoCare direct rather than to the card's non-covered tier.

Ozempic Savings Card

Commercially insured Ozempic patients can also pay as little as $25 per fill, with a maximum of $100 per month in savings and the offer good for up to 48 months. Each fill is defined as a 28-day supply.⁴

Who Savings Cards Exclude

Both Novo Nordisk savings cards are ineligible for patients enrolled in any federal healthcare program, including Medicare, Medicaid, TRICARE, and VA. This is the standard rule for manufacturer copay cards under US healthcare law and is not specific to semaglutide.

How much does compounded semaglutide cost in 2026?

Where still available, compounded semaglutide from licensed 503A and 503B compounding pharmacies typically runs $200 to $500 per month in 2026, plus $40 to $100 in membership or consultation fees at many telehealth platforms.⁶ That pricing remains the most affordable path for cash-pay patients who can find a remaining provider, but the regulatory category narrowed sharply in 2025 and again in April 2026.

From 2022 through most of 2024, semaglutide injection sat on the FDA drug shortage list, which lets licensed pharmacies (503A) and outsourcing facilities (503B) produce copies of FDA-approved products that would otherwise be prohibited. After the FDA confirmed the shortage was resolved in early 2025, state-licensed pharmacies had until April 22, 2025 to wind down, and outsourcing facilities until May 22, 2025. The shortage status is currently listed as Resolved on the FDA's drug shortages database.⁵⁷

In April 2026, the FDA clarified that a compounded product pairing semaglutide with vitamin B12 is treated as essentially a copy of Wegovy or Ozempic when the semaglutide strength is within 10 percent of the commercial equivalents. A narrow exception applies for compounders filling four or fewer prescriptions of a given compounded product per calendar month.⁵ Many smaller telehealth providers exited semaglutide compounding entirely; some pivoted patients toward NovoCare direct cash-pay. Our compounded-semaglutide explainer covers the regulatory pathway in depth.

What this means for cost in 2026:

• Pricing is variable and provider-specific, typically $200 to $500 per month, with some tracker sites reporting promotional lows around $129 to $150.⁶⁸ Telehealth platform fees add $40 to $100 per month.
• Insurance and savings cards do not apply. Most plans exclude compounded medications outright.⁸
• Quality depends on the compounding pharmacy's licensing. A reputable provider will share the pharmacy's name, state licensing, and 503B registration on request.

Does insurance cover semaglutide?

For most patients, whether insurance covers semaglutide matters more than any other variable. A covered plan can drop the monthly cost from $1,349 to $25, a 54-fold difference. An excluded plan leaves the patient paying close to the full retail price.

Commercial insurance coverage falls into three patterns:

Scenario 1: Covered on Formulary

The plan's preferred drug list includes Wegovy or Ozempic, usually on a mid-tier or specialty-tier level. Copays typically run $25 to $200 per month depending on tier. Prior authorization is common, especially for Wegovy, and typically requires documentation of BMI of 30 or higher (or 27 or higher with a weight-related comorbidity), documentation of previous weight-loss attempts, and sometimes enrollment in a supporting lifestyle program.

Scenario 2: Covered After Prior Authorization

The plan will cover semaglutide once clinical criteria are documented and approved. The paperwork burden falls on the prescriber's office, with the patient's cooperation on records and documentation. Approval rates vary by payer, but for patients who clearly meet BMI and comorbidity criteria, approvals are common. Ozempic prior authorizations for documented Type 2 diabetes are straightforward; Wegovy authorizations for obesity have historically been more variable across plans.

Scenario 3: Excluded

Some commercial plans, particularly smaller employer self-funded plans, explicitly exclude weight-loss medications. For these patients, the savings card's non-covered tier or NovoCare direct is the fallback path for Wegovy. For Ozempic, where the indication is Type 2 diabetes, outright exclusion is rarer.

Does Medicare, Medicaid, or an HSA cover semaglutide?

Medicare

Medicare Part D does not cover any prescription used primarily for weight loss, by statute (Medicare Modernization Act of 2003). Wegovy is therefore not covered for obesity on any Medicare plan, though it may be covered on some Part D plans for its cardiovascular-risk-reduction indication in adults with established cardiovascular disease. Ozempic and Rybelsus may be covered for Type 2 diabetes, subject to plan formulary. The CMS Plan Finder is the authoritative coverage lookup.

Medicaid and VA

Medicaid coverage varies by state. Most state programs cover Ozempic for Type 2 diabetes with prior authorization; Wegovy coverage for obesity is less consistent. The VA covers semaglutide for enrolled veterans meeting specific clinical criteria, with copays based on priority group and service connection. State and VA formulary decisions change annually, so current coverage is worth confirming directly.

HSA and FSA

Both HSAs and FSAs can be used for semaglutide when prescribed, which effectively discounts the out-of-pocket cost by your marginal tax rate. For a patient in a 24 percent federal bracket paying $349 per month through NovoCare direct, HSA dollars turn that into about $265 after-tax equivalent.

What extra costs come with semaglutide beyond the prescription?

Monthly drug cost is the headline figure, but four additional line items are worth budgeting for:

• Injection supplies. Wegovy and Ozempic ship as prefilled pens but still require needle tips ($5 to $20/month), alcohol prep pads ($2 to $5/month), and sharps disposal ($10 to $20 every few months). Rybelsus tablets have no injection cost.
• Lab work. Baseline and periodic labs (A1C, fasting glucose, lipid panel, liver enzymes) run roughly $100 to $300 per panel at direct-to-consumer labs for cash-pay patients; usually covered for insured patients.
• Clinician follow-ups. Typically quarterly. Bundled into the monthly fee on most compounded-semaglutide telehealth platforms; otherwise $100 to $250 per visit cash-pay.
• Insurance appeals. Time cost is real for denied Wegovy claims, even when the prescriber's office handles most of the paperwork.

For a cash-pay Wegovy patient on the $349 NovoCare direct price, the true monthly cost is closer to $370 to $390 once supplies and amortized lab costs are included.

What is the cheapest way to get semaglutide in 2026?

The cheapest legitimate semaglutide cost for you depends on three questions:

1. Do you have commercial insurance that covers Wegovy or Ozempic? If yes, apply for the manufacturer savings card and ask your prescriber to submit a prior authorization. Covered patients pay $25 per month plus applicable deductibles, with savings capped at $100 per month.
2. If not covered by insurance, are you on Wegovy? If yes, NovoCare Pharmacy direct cash-pay at $199 per month for the 0.25 mg and 0.5 mg starter doses (through June 30, 2026), then $349 per month for standard maintenance pens, is the cheapest path to FDA-approved Wegovy. For Rybelsus, NovoCare direct at $149 per month for 1.5 mg and 4 mg tablets is the cheapest oral option.
3. Are you open to compounded semaglutide? Where still available, licensed 503A and 503B compounding pharmacies produce personalized semaglutide formulations at monthly prices that can undercut NovoCare direct, though the available providers narrowed sharply in 2025 and again in April 2026 after the FDA's "essentially a copy" clarification. Ask your provider which pharmacy dispenses your prescription, what the formulation contains, and how it qualifies under the personalized 503A or 503B framework. For provider-by-provider context, see our compounded-semaglutide explainer.

For patients who reach the maintenance dose, total annual semaglutide cost varies enormously:

• Insurance + savings card (any product): ~$300 per year
• NovoCare Pharmacy direct, Wegovy 2.4 mg: ~$4,188 per year
• NovoCare Pharmacy direct, Rybelsus 4 mg: ~$1,788 per year (intro), then ~$2,388 per year
• Retail pharmacy list price, Wegovy: ~$16,200 per year
• Compounded personalized semaglutide formulation (where available): ~$2,400 to $6,000 per year⁶

Frequently Asked Questions

How much does semaglutide cost per month in 2026?

Brand-name semaglutide lists at $1,349.02 per package for Wegovy and $1,027.51 per fill for Ozempic. Through NovoCare Pharmacy direct, Wegovy starts at $199 for 0.25 mg and 0.5 mg pens (through June 30, 2026), then $349 for standard pens. With commercial insurance and a savings card, eligible patients pay as little as $25 per fill.

Is compounded semaglutide still legal in 2026?

The FDA's enforcement discretion for compounded semaglutide ended on April 22, 2025 for state-licensed 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. In April 2026, the FDA further clarified that semaglutide combined with vitamin B12 within 10 percent of commercial strengths is essentially a copy of Wegovy or Ozempic. Personalized formulations remain available through fewer providers.

Does insurance cover semaglutide for weight loss?

Commercial coverage of Wegovy for obesity is uneven. A growing share of large-employer plans cover it with prior authorization, BMI documentation, and step-therapy requirements. Medicare Part D does not cover any prescription used primarily for weight loss. Ozempic and Rybelsus for Type 2 diabetes are more widely covered.

How do I get semaglutide for $25 per month?

The $25 price applies through Novo Nordisk's savings cards for Wegovy and Ozempic. Eligibility requires commercial prescription insurance that covers the drug, a US prescription, and exclusion of patients enrolled in federal programs (Medicare, Medicaid, TRICARE, VA). Both cards cap savings at $100 per month; the Ozempic card is good for up to 48 months.

Is there a generic version of semaglutide?

No. Semaglutide is under patent protection held by Novo Nordisk, with key US patents not expected to expire until the early 2030s. Compounded semaglutide is not a generic; it is produced under a separate regulatory pathway for custom-prepared medications, not the FDA's abbreviated new drug application process that brings generics to market.

What is NovoCare Pharmacy direct cash-pay pricing?

NovoCare Pharmacy is Novo Nordisk's direct-to-patient cash-pay channel. Wegovy runs $199/month for 0.25 mg and 0.5 mg pens through June 30, 2026, then $349/month for the 0.25 mg through 2.4 mg standard pens and $399/month for the Wegovy HD 7.2 mg pen. Rybelsus runs $149/month for the 1.5 mg and 4 mg tablets, stepping up after August 31, 2026.

The Bottom Line

Semaglutide cost in 2026 is no longer a single number, and the spread from cheapest to most expensive legitimate path is roughly 54-to-1. For insured patients, apply the savings card for the $25 price (capped at $100/month in savings). For cash-pay patients on Wegovy, NovoCare Pharmacy direct at $199 to $399 per month is the cheapest FDA-approved path. Compounded alternatives still exist but have narrowed twice since early 2025. Before committing to any path, confirm current pricing with the provider and verify insurance coverage with your plan. For the molecule comparison, see our semaglutide vs. tirzepatide guide.